{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T18:11:29Z","timestamp":1793729489617,"version":"4.6.1"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Key Program for Science & Technology of Henan Province","award":["252102311056"],"award-info":[{"award-number":["252102311056"]}]},{"name":"Key Program for Science & Technology of Henan Province","award":["242102311153"],"award-info":[{"award-number":["242102311153"]}]},{"name":"Key Program for Science & Technology of Henan Province","award":["242102310065"],"award-info":[{"award-number":["242102310065"]}]},{"name":"Development Program for Science & Technology of Kaifeng City","award":["2303137"],"award-info":[{"award-number":["2303137"]}]},{"name":"Development Program for Science & Technology of Kaifeng City","award":["2403091"],"award-info":[{"award-number":["2403091"]}]},{"name":"Province and Ministry Co-construction Program for Medical Science & Technology of Henan Province","award":["LHGJ20230435"],"award-info":[{"award-number":["LHGJ20230435"]}]},{"name":"Innovative & Entrepreneurial Program for College Student","award":["202510475038"],"award-info":[{"award-number":["202510475038"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-07053-6","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T12:24:52Z","timestamp":1759407892000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["CBP\/p300, a promising therapeutic target for prostate cancer"],"prefix":"10.1186","volume":"23","author":[{"given":"Hongtao","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8117-4616","authenticated-orcid":false,"given":"Xiaobo","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqing","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"7053_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"7053_CR2","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 update on prostate cancer epidemiology and risk factors-a systematic review. Eur Urol. 2023;84:191\u2013206.","journal-title":"Eur Urol"},{"key":"7053_CR3","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s11427-022-2218-x","volume":"66","author":"W Ju","year":"2023","unstructured":"Ju W, Zheng R, Zhang S, Zeng H, Sun K, Wang S, et al. Cancer statistics in Chinese older people, 2022: current burden, time trends, and comparisons with the US, Japan, and the Republic of Korea. Sci China Life Sci. 2023;66:1079\u201391.","journal-title":"Sci China Life Sci"},{"key":"7053_CR4","doi-asserted-by":"crossref","unstructured":"Pranav LP, Jaggi M, Chauhan SC, Yallapu MM. Biomolecule-functionalized nanoformulations for prostate cancer theranostics. J Adv Res. 2023;51:197\u2013217.","DOI":"10.1016\/j.jare.2022.11.001"},{"key":"7053_CR5","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1186\/s12951-023-02219-0","volume":"21","author":"H Chen","year":"2023","unstructured":"Chen H, Pang B, Zhou C, Han M, Gong J, Li Y, et al. Prostate cancer-derived small extracellular vesicle proteins: the hope in diagnosis, prognosis, and therapeutics. J Nanobiotechnology. 2023;21:480.","journal-title":"J Nanobiotechnology"},{"key":"7053_CR6","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med. 2014;371:1028\u201338.","journal-title":"N Engl J Med"},{"key":"7053_CR7","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1038\/s41401-019-0237-5","volume":"40","author":"LJ Zou","year":"2019","unstructured":"Zou LJ, Xiang QP, Xue XQ, Zhang C, Li CC, Wang C, et al. Y08197 is a novel and selective CBP\/EP300 bromodomain inhibitor for the treatment of prostate cancer. Acta Pharmacol Sin. 2019;40:1436\u201347.","journal-title":"Acta Pharmacol Sin"},{"key":"7053_CR8","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1158\/2159-8290.CD-21-0184","volume":"11","author":"RU Rasool","year":"2021","unstructured":"Rasool RU, Natesan R, Asangani IA. Toppling the HAT to treat lethal prostate cancer. Cancer Discov. 2021;11:1011\u20133.","journal-title":"Cancer Discov"},{"key":"7053_CR9","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1002\/pros.23939","volume":"80","author":"X Chen","year":"2020","unstructured":"Chen X, Liu J, Cheng L, Li C, Zhang Z, Bai Y, et al. Inhibition of noncanonical Wnt pathway overcomes enzalutamide resistance in castration-resistant prostate cancer. Prostate. 2020;80:256\u201366.","journal-title":"Prostate"},{"key":"7053_CR10","doi-asserted-by":"publisher","first-page":"20853","DOI":"10.1074\/jbc.M000660200","volume":"275","author":"M Fu","year":"2000","unstructured":"Fu M, Wang C, Reutens AT, Wang J, Angeletti RH, Siconolfi-Baez L, et al. P300 and p300\/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem. 2000;275:20853\u201360.","journal-title":"J Biol Chem"},{"key":"7053_CR11","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1038\/s41388-020-1270-z","volume":"39","author":"J Liu","year":"2020","unstructured":"Liu J, He D, Cheng L, Huang C, Zhang Y, Rao X, et al. P300\/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer. Oncogene. 2020;39:3939\u201351.","journal-title":"Oncogene"},{"key":"7053_CR12","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/path.6280","volume":"263","author":"N Choo","year":"2024","unstructured":"Choo N, Keerthikumar S, Ramm S, Ashikari D, Teng L, Niranjan B, et al. Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer. J Pathol. 2024;263:242\u201356.","journal-title":"J Pathol"},{"key":"7053_CR13","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2159-8290.CD-20-0751","volume":"11","author":"J Welti","year":"2021","unstructured":"Welti J, Sharp A, Brooks N, Yuan W, McNair C, Chand SN, et al. Targeting the p300\/CBP axis in lethal prostate cancer. Cancer Discov. 2021;11:1118\u201337.","journal-title":"Cancer Discov"},{"key":"7053_CR14","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1007\/s00018-012-1254-4","volume":"70","author":"F Wang","year":"2013","unstructured":"Wang F, Marshall CB, Ikura M. Transcriptional\/epigenetic regulator CBP\/p300 in tumorigenesis: structural and functional versatility in target recognition. Cell Mol Life Sci. 2013;70:3989\u20134008.","journal-title":"Cell Mol Life Sci"},{"key":"7053_CR15","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.sbi.2008.09.004","volume":"18","author":"L Wang","year":"2008","unstructured":"Wang L, Tang Y, Cole PA, Marmorstein R. Structure and chemistry of the p300\/CBP and Rtt109 histone acetyltransferases: implications for histone acetyltransferase evolution and function. Curr Opin Struct Biol. 2008;18:741\u20137.","journal-title":"Curr Opin Struct Biol"},{"key":"7053_CR16","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1021\/cr500452k","volume":"115","author":"BM Dancy","year":"2015","unstructured":"Dancy BM, Cole PA. Protein lysine acetylation by p300\/CBP. Chem Rev. 2015;115:2419\u201352.","journal-title":"Chem Rev"},{"key":"7053_CR17","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1038\/s41586-018-0621-1","volume":"562","author":"E Ortega","year":"2018","unstructured":"Ortega E, Rengachari S, Ibrahim Z, Hoghoughi N, Gaucher J, Holehouse AS, et al. Transcription factor dimerization activates the p300 acetyltransferase. Nature. 2018;562:538\u201344.","journal-title":"Nature"},{"key":"7053_CR18","doi-asserted-by":"publisher","first-page":"E5335","DOI":"10.1073\/pnas.1703105114","volume":"114","author":"S Park","year":"2017","unstructured":"Park S, Stanfield RL, Martinez-Yamout MA, Dyson HJ, Wilson IA, Wright PE. Role of the CBP catalytic core in intramolecular SUMOylation and control of histone H3 acetylation. Proc Natl Acad Sci U S A. 2017;114:E5335\u201342.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7053_CR19","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.str.2008.01.010","volume":"16","author":"L Zeng","year":"2008","unstructured":"Zeng L, Zhang Q, Gerona-Navarro G, Moshkina N, Zhou MM. Structural basis of site-specific histone recognition by the bromodomains of human coactivators PCAF and CBP\/p300. Structure. 2008;16:643\u201352.","journal-title":"Structure"},{"key":"7053_CR20","doi-asserted-by":"publisher","DOI":"10.3410\/B1-98","volume":"1","author":"CM Chiang","year":"2009","unstructured":"Chiang CM. Brd4 engagement from chromatin targeting to transcriptional regulation: selective contact with acetylated histone H3 and H4. F1000 Biol Rep. 2009;1:98.","journal-title":"F1000 Biol Rep"},{"key":"7053_CR21","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1038\/s41388-024-03148-4","volume":"43","author":"S Sardar","year":"2024","unstructured":"Sardar S, McNair CM, Ravindranath L, Chand SN, Yuan W, Bogdan D, et al. AR coactivators, CBP\/p300, are critical mediators of DNA repair in prostate cancer. Oncogene. 2024;43:3197\u2013213.","journal-title":"Oncogene"},{"key":"7053_CR22","doi-asserted-by":"publisher","first-page":"4303","DOI":"10.1074\/jbc.RA119.011078","volume":"295","author":"MR Lochhead","year":"2020","unstructured":"Lochhead MR, Brown AD, Kirlin AC, Chitayat S, Munro K, Findlay JE, et al. Structural insights into TAZ2 domain-mediated CBP\/p300 recruitment by transactivation domain 1 of the lymphopoietic transcription factor E2A. J Biol Chem. 2020;295:4303\u201315.","journal-title":"J Biol Chem"},{"key":"7053_CR23","doi-asserted-by":"publisher","first-page":"5362","DOI":"10.1038\/s41467-023-41245-2","volume":"14","author":"L Xu","year":"2023","unstructured":"Xu L, Xuan H, He W, Zhang L, Huang M, Li K, et al. TAZ2 truncation confers overactivation of p300 and cellular vulnerability to HDAC inhibition. Nat Commun. 2023;14:5362.","journal-title":"Nat Commun"},{"key":"7053_CR24","doi-asserted-by":"publisher","first-page":"16604","DOI":"10.1074\/jbc.RA119.009845","volume":"294","author":"A Garg","year":"2019","unstructured":"Garg A, Orru R, Ye W, Distler U, Chojnacki JE, K\u00f6hn M, et al. Structural and mechanistic insights into the interaction of the circadian transcription factor BMAL1 with the KIX domain of the CREB-binding protein. J Biol Chem. 2019;294:16604\u201319.","journal-title":"J Biol Chem"},{"key":"7053_CR25","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1021\/cb4002188","volume":"8","author":"S Br\u00fcschweiler","year":"2013","unstructured":"Br\u00fcschweiler S, Konrat R, Tollinger M. Allosteric communication in the KIX domain proceeds through dynamic repacking of the hydrophobic core. ACS Chem Biol. 2013;8:1600\u201310.","journal-title":"ACS Chem Biol"},{"key":"7053_CR26","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abl4618","volume":"8","author":"KB Kim","year":"2022","unstructured":"Kim KB, Kabra A, Kim DW, Xue Y, Huang Y, Hou PC, et al. KIX domain determines a selective tumor-promoting role for EP300 and its vulnerability in small cell lung cancer. Sci Adv. 2022;8:eabl4618.","journal-title":"Sci Adv"},{"key":"7053_CR27","doi-asserted-by":"publisher","first-page":"247","DOI":"10.18632\/aging.100453","volume":"4","author":"DC Bedford","year":"2012","unstructured":"Bedford DC, Brindle PK. Is histone acetylation the most important physiological function for CBP and p300? Aging (Albany NY). 2012;4:247\u201355.","journal-title":"Aging (Albany NY)"},{"key":"7053_CR28","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1242\/jcs.114.13.2363","volume":"114","author":"HM Chan","year":"2001","unstructured":"Chan HM, La Thangue NB. P300\/CBP proteins: HATs for transcriptional bridges and scaffolds. J Cell Sci. 2001;114:2363\u201373.","journal-title":"J Cell Sci"},{"key":"7053_CR29","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1038\/376348a0","volume":"376","author":"F Petrij","year":"1995","unstructured":"Petrij F, Giles RH, Dauwerse HG, Saris JJ, Hennekam RC, Masuno M, et al. Rubinstein-Taybi syndrome caused by mutations in the transcriptional co-activator CBP. Nature. 1995;376:348\u201351.","journal-title":"Nature"},{"key":"7053_CR30","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1158\/1078-0432.512.11.2","volume":"11","author":"M Kishimoto","year":"2005","unstructured":"Kishimoto M, Kohno T, Okudela K, Otsuka A, Sasaki H, Tanabe C, et al. Mutations and deletions of the CBP gene in human lung cancer. Clin Cancer Res. 2005;11:512\u20139.","journal-title":"Clin Cancer Res"},{"key":"7053_CR31","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature09727","volume":"471","author":"CG Mullighan","year":"2011","unstructured":"Mullighan CG, Zhang J, Kasper LH, Lerach S, Payne-Turner D, Phillips LA, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature. 2011;471:235\u20139.","journal-title":"Nature"},{"key":"7053_CR32","doi-asserted-by":"publisher","first-page":"4366","DOI":"10.1158\/1538-7445.AM2024-4366","volume":"84","author":"JA Rodrigues","year":"2024","unstructured":"Rodrigues JA, Luo J, Sabel AR, Chen Z, Tang X, Kuo F, et al. Abstract 4366: loss of EP300 triggers IL-1\u03b1 signaling and subsequent activation of the IL-6\/JAK\/STAT3 axis to drive oncogenesis in bladder cancer. Cancer Res. 2024;84:4366.","journal-title":"Cancer Res"},{"key":"7053_CR33","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00432-001-0317-y","volume":"128","author":"MV Karamouzis","year":"2002","unstructured":"Karamouzis MV, Papadas T, Varakis I, Sotiropoulou-Bonikou G, Papavassiliou AG. Induction of the CBP transcriptional co-activator early during laryngeal carcinogenesis. J Cancer Res Clin Oncol. 2002;128:135\u201340.","journal-title":"J Cancer Res Clin Oncol"},{"key":"7053_CR34","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1038\/cr.2007.10","volume":"17","author":"MV Karamouzis","year":"2007","unstructured":"Karamouzis MV, Konstantinopoulos PA, Papavassiliou AG. Roles of CREB-binding protein (CBP)\/p300 in respiratory epithelium tumorigenesis. Cell Res. 2007;17:324\u201332.","journal-title":"Cell Res"},{"key":"7053_CR35","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1158\/0008-5472.CAN-18-2331","volume":"79","author":"E Kim","year":"2019","unstructured":"Kim E, Zucconi BE, Wu M, Nocco SE, Meyers DJ, McGee JS, et al. MITF expression predicts therapeutic vulnerability to p300 inhibition in human melanoma. Cancer Res. 2019;79:2649\u201361.","journal-title":"Cancer Res"},{"key":"7053_CR36","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1158\/2159-8290.CD-17-0375","volume":"7","author":"X Yao","year":"2017","unstructured":"Yao X, Tan J, Lim KJ, Koh J, Ooi WF, Li Z, et al. VHL deficiency drives enhancer activation of oncogenes in clear cell renal cell carcinoma. Cancer Discov. 2017;7:1284\u2013305.","journal-title":"Cancer Discov"},{"key":"7053_CR37","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.molcel.2004.06.030","volume":"15","author":"J Yu","year":"2004","unstructured":"Yu J, de Belle I, Liang H, Adamson ED. Coactivating factors p300 and CBP are transcriptionally crossregulated by Egr1 in prostate cells, leading to divergent responses. Mol Cell. 2004;15:83\u201394.","journal-title":"Mol Cell"},{"key":"7053_CR38","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.chembiol.2023.11.014","volume":"30","author":"LK Xu","year":"2023","unstructured":"Xu LK, Ntziachristos P. Knocking off cancer\u2019s HAT: CSS1477 disrupts oncogenic programs. Cell Chem Biol. 2023;30:1505\u20137.","journal-title":"Cell Chem Biol"},{"key":"7053_CR39","doi-asserted-by":"publisher","first-page":"4103","DOI":"10.1038\/s41467-023-39735-4","volume":"14","author":"M Kikuchi","year":"2023","unstructured":"Kikuchi M, Morita S, Wakamori M, Sato S, Uchikubo-Kamo T, Suzuki T, et al. Epigenetic mechanisms to propagate histone acetylation by p300\/CBP. Nat Commun. 2023;14:4103.","journal-title":"Nat Commun"},{"key":"7053_CR40","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41588-023-01348-4","volume":"55","author":"T Narita","year":"2023","unstructured":"Narita T, Higashijima Y, Kilic S, Liebner T, Walter J, Choudhary C. Acetylation of histone H2B marks active enhancers and predicts CBP\/p300 target genes. Nat Genet. 2023;55:679\u201392.","journal-title":"Nat Genet"},{"key":"7053_CR41","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1016\/j.molcel.2021.03.008","volume":"81","author":"T Narita","year":"2021","unstructured":"Narita T, Ito S, Higashijima Y, Chu WK, Neumann K, Walter J, et al. Enhancers are activated by p300\/CBP activity-dependent PIC assembly, RNAPII recruitment, and pause release. Mol Cell. 2021;81:2166-82.e2166.","journal-title":"Mol Cell"},{"key":"7053_CR42","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1158\/1535-7163.MCT-14-0865","volume":"14","author":"P Chatterjee","year":"2015","unstructured":"Chatterjee P, Choudhary GS, Alswillah T, Xiong X, Heston WD, Magi-Galluzzi C, et al. The tmprss2-erg gene fusion blocks XRCC4-mediated nonhomologous end-joining repair and radiosensitizes prostate cancer cells to PARP inhibition. Mol Cancer Ther. 2015;14:1896\u2013906.","journal-title":"Mol Cancer Ther"},{"key":"7053_CR43","doi-asserted-by":"publisher","first-page":"38319","DOI":"10.18632\/oncotarget.9513","volume":"7","author":"AM Blee","year":"2016","unstructured":"Blee AM, Liu S, Wang L, Huang H. BET bromodomain-mediated interaction between ERG and BRD4 promotes prostate cancer cell invasion. Oncotarget. 2016;7:38319\u201332.","journal-title":"Oncotarget"},{"key":"7053_CR44","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.molcel.2015.04.011","volume":"58","author":"JS Roe","year":"2015","unstructured":"Roe JS, Mercan F, Rivera K, Pappin DJ, Vakoc CR. BET bromodomain inhibition suppresses the function of hematopoietic transcription factors in acute myeloid leukemia. Mol Cell. 2015;58:1028\u201339.","journal-title":"Mol Cell"},{"key":"7053_CR45","doi-asserted-by":"publisher","first-page":"10442","DOI":"10.1128\/MCB.25.23.10442-10453.2005","volume":"25","author":"WY Chen","year":"2005","unstructured":"Chen WY, Juan LJ, Chung BC. SF-1 (nuclear receptor 5A1) activity is activated by cyclic AMP via p300-mediated recruitment to active foci, acetylation, and increased DNA binding. Mol Cell Biol. 2005;25:10442\u201353.","journal-title":"Mol Cell Biol"},{"key":"7053_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2019.110509","volume":"495","author":"CS Anyetei-Anum","year":"2019","unstructured":"Anyetei-Anum CS, Evans RM, Back AM, Roggero VR, Allison LA. Acetylation modulates thyroid hormone receptor intracellular localization and intranuclear mobility. Mol Cell Endocrinol. 2019;495:110509.","journal-title":"Mol Cell Endocrinol"},{"key":"7053_CR47","doi-asserted-by":"publisher","first-page":"18375","DOI":"10.1074\/jbc.M100800200","volume":"276","author":"C Wang","year":"2001","unstructured":"Wang C, Fu M, Angeletti RH, Siconolfi-Baez L, Reutens AT, Albanese C, et al. Direct acetylation of the estrogen receptor alpha hinge region by p300 regulates transactivation and hormone sensitivity. J Biol Chem. 2001;276:18375\u201383.","journal-title":"J Biol Chem"},{"key":"7053_CR48","doi-asserted-by":"publisher","first-page":"2877","DOI":"10.1210\/me.2007-0107","volume":"21","author":"WX Zhao","year":"2007","unstructured":"Zhao WX, Tian M, Zhao BX, Li GD, Liu B, Zhan YY, et al. Orphan receptor TR3 attenuates the p300-induced acetylation of retinoid X receptor-alpha. Mol Endocrinol. 2007;21:2877\u201389.","journal-title":"Mol Endocrinol"},{"key":"7053_CR49","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.cmet.2009.09.009","volume":"10","author":"JK Kemper","year":"2009","unstructured":"Kemper JK, Xiao Z, Ponugoti B, Miao J, Fang S, Kanamaluru D, et al. FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. Cell Metab. 2009;10:392\u2013404.","journal-title":"Cell Metab"},{"key":"7053_CR50","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1074\/jbc.M113.517896","volume":"289","author":"HH Chung","year":"2014","unstructured":"Chung HH, Sze SK, Tay AS, Lin VC. Acetylation at lysine 183 of progesterone receptor by p300 accelerates DNA binding kinetics and transactivation of direct target genes. J Biol Chem. 2014;289:2180\u201394.","journal-title":"J Biol Chem"},{"key":"7053_CR51","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1210\/me.2002-0384","volume":"17","author":"A W\u00e4rnmark","year":"2003","unstructured":"W\u00e4rnmark A, Treuter E, Wright AP, Gustafsson JA. Activation functions 1 and 2 of nuclear receptors: molecular strategies for transcriptional activation. Mol Endocrinol. 2003;17:1901\u20139.","journal-title":"Mol Endocrinol"},{"key":"7053_CR52","doi-asserted-by":"publisher","first-page":"4267","DOI":"10.1200\/JCO.23.00433","volume":"41","author":"C Dai","year":"2023","unstructured":"Dai C, Dehm SM, Sharifi N. Targeting the androgen signaling axis in prostate cancer. J Clin Oncol. 2023;41:4267\u201378.","journal-title":"J Clin Oncol"},{"key":"7053_CR53","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13045-015-0225-2","volume":"8","author":"MT Schweizer","year":"2015","unstructured":"Schweizer MT, Yu EY. Persistent androgen receptor addiction in castration-resistant prostate cancer. J Hematol Oncol. 2015;8:128.","journal-title":"J Hematol Oncol"},{"key":"7053_CR54","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1210\/me.2008-0089","volume":"22","author":"DF Smith","year":"2008","unstructured":"Smith DF, Toft DO. Minireview: the intersection of steroid receptors with molecular chaperones: observations and questions. Mol Endocrinol. 2008;22:2229\u201340.","journal-title":"Mol Endocrinol"},{"key":"7053_CR55","doi-asserted-by":"publisher","first-page":"858","DOI":"10.3389\/fonc.2019.00858","volume":"9","author":"Q Feng","year":"2019","unstructured":"Feng Q, He B. Androgen receptor signaling in the development of castration-resistant prostate cancer. Front Oncol. 2019;9:858.","journal-title":"Front Oncol"},{"key":"7053_CR56","doi-asserted-by":"publisher","first-page":"4000","DOI":"10.1074\/jbc.M111.300194","volume":"287","author":"I Ianculescu","year":"2012","unstructured":"Ianculescu I, Wu DY, Siegmund KD, Stallcup MR. Selective roles for cAMP response element-binding protein binding protein and p300 protein as coregulators for androgen-regulated gene expression in advanced prostate cancer cells. J Biol Chem. 2012;287:4000\u201313.","journal-title":"J Biol Chem"},{"key":"7053_CR57","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/42750","volume":"387","author":"DM Heery","year":"1997","unstructured":"Heery DM, Kalkhoven E, Hoare S, Parker MG. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature. 1997;387:733\u20136.","journal-title":"Nature"},{"key":"7053_CR58","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.molcel.2020.06.031","volume":"79","author":"X Yu","year":"2020","unstructured":"Yu X, Yi P, Hamilton RA, Shen H, Chen M, Foulds CE, et al. Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes. Mol Cell. 2020;79:812-823.e814.","journal-title":"Mol Cell"},{"key":"7053_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189186","volume":"1879","author":"Y Hou","year":"2024","unstructured":"Hou Y, Zhao Z, Li P, Cao Y, Zhang Y, Guo C, et al. Combination therapies with Wnt signaling inhibition: a better choice for prostate cancer treatment. Biochim Biophys Acta Rev Cancer. 2024;1879:189186.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"7053_CR60","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1101\/gad.1424006","volume":"20","author":"K Willert","year":"2006","unstructured":"Willert K, Jones KA. Wnt signaling: is the party in the nucleus? Genes Dev. 2006;20:1394\u2013404.","journal-title":"Genes Dev"},{"key":"7053_CR61","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S0092-8674(00)80352-9","volume":"90","author":"AH Huber","year":"1997","unstructured":"Huber AH, Nelson WJ, Weis WI. Three-dimensional structure of the armadillo repeat region of beta-catenin. Cell. 1997;90:871\u201382.","journal-title":"Cell"},{"key":"7053_CR62","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1016\/S1097-2765(03)00234-X","volume":"11","author":"G Wu","year":"2003","unstructured":"Wu G, Xu G, Schulman BA, Jeffrey PD, Harper JW, Pavletich NP. Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase. Mol Cell. 2003;11:1445\u201356.","journal-title":"Mol Cell"},{"key":"7053_CR63","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.str.2007.12.021","volume":"16","author":"Y Xing","year":"2008","unstructured":"Xing Y, Takemaru K, Liu J, Berndt JD, Zheng JJ, Moon RT, et al. Crystal structure of a full-length beta-catenin. Structure. 2008;16:478\u201387.","journal-title":"Structure"},{"key":"7053_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.124155","volume":"238","author":"AD Brown","year":"2023","unstructured":"Brown AD, Cranstone C, Dupr\u00e9 DJ, Langelaan DN. \u0392-catenin interacts with the TAZ1 and TAZ2 domains of CBP\/p300 to activate gene transcription. Int J Biol Macromol. 2023;238:124155.","journal-title":"Int J Biol Macromol"},{"key":"7053_CR65","doi-asserted-by":"publisher","first-page":"35170","DOI":"10.1074\/jbc.C000258200","volume":"275","author":"M Miyagishi","year":"2000","unstructured":"Miyagishi M, Fujii R, Hatta M, Yoshida E, Araya N, Nagafuchi A, et al. Regulation of Lef-mediated transcription and p53-dependent pathway by associating beta-catenin with CBP\/p300. J Biol Chem. 2000;275:35170\u20135.","journal-title":"J Biol Chem"},{"key":"7053_CR66","doi-asserted-by":"publisher","first-page":"25562","DOI":"10.1074\/jbc.M201196200","volume":"277","author":"D Wolf","year":"2002","unstructured":"Wolf D, Rodova M, Miska EA, Calvet JP, Kouzarides T. Acetylation of beta-catenin by CREB-binding protein (CBP). J Biol Chem. 2002;277:25562\u20137.","journal-title":"J Biol Chem"},{"key":"7053_CR67","doi-asserted-by":"publisher","first-page":"9063","DOI":"10.1128\/MCB.25.20.9063-9072.2005","volume":"25","author":"S Hino","year":"2005","unstructured":"Hino S, Tanji C, Nakayama KI, Kikuchi A. Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase stabilizes beta-catenin through inhibition of its ubiquitination. Mol Cell Biol. 2005;25:9063\u201372.","journal-title":"Mol Cell Biol"},{"key":"7053_CR68","doi-asserted-by":"publisher","first-page":"6591","DOI":"10.1073\/pnas.0811023106","volume":"106","author":"JC Ferreon","year":"2009","unstructured":"Ferreon JC, Lee CW, Arai M, Martinez-Yamout MA, Dyson HJ, Wright PE. Cooperative regulation of p53 by modulation of ternary complex formation with CBP\/p300 and HDM2. Proc Natl Acad Sci U S A. 2009;106:6591\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7053_CR69","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","volume":"8","author":"H Wang","year":"2023","unstructured":"Wang H, Guo M, Wei H, Chen Y. Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduct Target Ther. 2023;8:92.","journal-title":"Signal Transduct Target Ther"},{"key":"7053_CR70","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/358015a0","volume":"358","author":"DP Lane","year":"1992","unstructured":"Lane DP. Cancer. p53, guardian of the genome. Nature. 1992;358:15\u20136.","journal-title":"Nature"},{"key":"7053_CR71","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41588-018-0204-y","volume":"50","author":"AO Giacomelli","year":"2018","unstructured":"Giacomelli AO, Yang X, Lintner RE, McFarland JM, Duby M, Kim J, et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat Genet. 2018;50:1381\u20137.","journal-title":"Nat Genet"},{"key":"7053_CR72","doi-asserted-by":"publisher","first-page":"637.e617","DOI":"10.1016\/j.urolonc.2020.03.001","volume":"38","author":"C Nientiedt","year":"2020","unstructured":"Nientiedt C, Endris V, Jenzer M, Mansour J, Sedehi NTP, Pecqueux C, et al. High prevalence of DNA damage repair gene defects and TP53 alterations in men with treatment-na\u00efve metastatic prostate cancer -Results from a prospective pilot study using a 37 gene panel. Urol Oncol. 2020;38:637.e617\u2013637.","journal-title":"Urol Oncol"},{"key":"7053_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107669","volume":"31","author":"MD Nyquist","year":"2020","unstructured":"Nyquist MD, Corella A, Coleman I, De Sarkar N, Kaipainen A, Ha G, et al. Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress. Cell Rep. 2020;31:107669.","journal-title":"Cell Rep"},{"key":"7053_CR74","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/j.urology.2007.11.005","volume":"71","author":"AV D'Amico","year":"2008","unstructured":"D\u2019Amico AV, Halabi S, Vollmer R, Loffredo M, McMahon E, Sanford B, et al. P53 protein expression status and recurrence in men treated with radiation and androgen suppression therapy for higher-risk prostate cancer: a prospective phase II Cancer and Leukemia Group B study (CALGB 9682). Urology. 2008;71:933\u20137.","journal-title":"Urology"},{"key":"7053_CR75","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1158\/1541-7786.MCR-14-0277-T","volume":"13","author":"Z Li","year":"2015","unstructured":"Li Z, Sun Y, Chen X, Squires J, Nowroozizadeh B, Liang C, et al. p53 mutation directs AURKA overexpression via miR-25 and FBXW7 in prostatic small cell neuroendocrine carcinoma. Mol Cancer Res. 2015;13:584\u201391.","journal-title":"Mol Cancer Res"},{"key":"7053_CR76","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/S1097-2765(00)80140-9","volume":"2","author":"SR Grossman","year":"1998","unstructured":"Grossman SR, Perez M, Kung AL, Joseph M, Mansur C, Xiao ZX, et al. P300\/MDM2 complexes participate in MDM2-mediated p53 degradation. Mol Cell. 1998;2:405\u201315.","journal-title":"Mol Cell"},{"key":"7053_CR77","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1021\/acs.biochem.9b00333","volume":"58","author":"R Ghosh","year":"2019","unstructured":"Ghosh R, Kaypee S, Shasmal M, Kundu TK, Roy S, Sengupta J. Tumor suppressor p53-mediated structural reorganization of the transcriptional coactivator p300. Biochemistry. 2019;58:3434\u201343.","journal-title":"Biochemistry"},{"key":"7053_CR78","doi-asserted-by":"publisher","first-page":"16275","DOI":"10.1073\/pnas.0904305106","volume":"106","author":"D Shi","year":"2009","unstructured":"Shi D, Pop MS, Kulikov R, Love IM, Kung AL, Grossman SR. CBP and p300 are cytoplasmic E4 polyubiquitin ligases for p53. Proc Natl Acad Sci U S A. 2009;106:16275\u201380.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7053_CR79","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s11033-019-05141-7","volume":"47","author":"Y Wang","year":"2020","unstructured":"Wang Y, Chen Y, Chen Q, Zhang X, Wang H, Wang Z, et al. The role of acetylation sites in the regulation of p53 activity. Mol Biol Rep. 2020;47:381\u201391.","journal-title":"Mol Biol Rep"},{"key":"7053_CR80","doi-asserted-by":"publisher","first-page":"4205","DOI":"10.1007\/s11033-010-0542-z","volume":"38","author":"MR Haghshenas","year":"2011","unstructured":"Haghshenas MR, Naeimi S, Talei A, Ghaderi A, Erfani N. Program death 1 (PD1) haplotyping in patients with breast carcinoma. Mol Biol Rep. 2011;38:4205\u201310.","journal-title":"Mol Biol Rep"},{"key":"7053_CR81","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cellimm.2014.05.006","volume":"290","author":"S Dai","year":"2014","unstructured":"Dai S, Jia R, Zhang X, Fang Q, Huang L. The PD-1\/PD-Ls pathway and autoimmune diseases. Cell Immunol. 2014;290:72\u20139.","journal-title":"Cell Immunol"},{"key":"7053_CR82","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12943-018-0928-4","volume":"18","author":"X Jiang","year":"2019","unstructured":"Jiang X, Wang J, Deng X, Xiong F, Ge J, Xiang B, et al. Role of the tumor microenvironment in PD-L1\/PD-1-mediated tumor immune escape. Mol Cancer. 2019;18:10.","journal-title":"Mol Cancer"},{"key":"7053_CR83","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nrc.2017.117","volume":"18","author":"S Spranger","year":"2018","unstructured":"Spranger S, Gajewski TF. Impact of oncogenic pathways on evasion of antitumour immune responses. Nat Rev Cancer. 2018;18:139\u201347.","journal-title":"Nat Rev Cancer"},{"key":"7053_CR84","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/pcan.2015.39","volume":"18","author":"AM Martin","year":"2015","unstructured":"Martin AM, Nirschl TR, Nirschl CJ, Francica BJ, Kochel CM, van Bokhoven A, et al. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer Prostatic Dis. 2015;18:325\u201332.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"7053_CR85","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1158\/1078-0432.CCR-15-2042","volume":"22","author":"H Gevensleben","year":"2016","unstructured":"Gevensleben H, Dietrich D, Golletz C, Steiner S, Jung M, Thiesler T, et al. The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer. Clin Cancer Res. 2016;22:1969\u201377.","journal-title":"Clin Cancer Res"},{"key":"7053_CR86","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s11523-015-0396-3","volume":"11","author":"F Massari","year":"2016","unstructured":"Massari F, Ciccarese C, Cali\u00f2 A, Munari E, Cima L, Porcaro AB, et al. Magnitude of PD-1, PD-L1 and T lymphocyte expression on tissue from castration-resistant prostate adenocarcinoma: an exploratory analysis. Target Oncol. 2016;11:345\u201351.","journal-title":"Target Oncol"},{"key":"7053_CR87","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41577-019-0264-y","volume":"20","author":"D Daassi","year":"2020","unstructured":"Daassi D, Mahoney KM, Freeman GJ. The importance of exosomal PDL1 in tumour immune evasion. Nat Rev Immunol. 2020;20:209\u201315.","journal-title":"Nat Rev Immunol"},{"key":"7053_CR88","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1084\/jem.20180870","volume":"216","author":"B Gong","year":"2019","unstructured":"Gong B, Kiyotani K, Sakata S, Nagano S, Kumehara S, Baba S, et al. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med. 2019;216:982\u20131000.","journal-title":"J Exp Med"},{"key":"7053_CR89","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 2017;19:1189\u2013201.","journal-title":"Cell Rep"},{"key":"7053_CR90","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-023-00846-y","volume":"21","author":"SA Lasser","year":"2024","unstructured":"Lasser SA, Ozbay Kurt FG, Arkhypov I, Utikal J, Umansky V. Myeloid-derived suppressor cells in cancer and cancer therapy. Nat Rev Clin Oncol. 2024;21:147\u201364.","journal-title":"Nat Rev Clin Oncol"},{"key":"7053_CR91","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1038\/s41388-025-03417-w","volume":"44","author":"J Liu","year":"2025","unstructured":"Liu J, Wang X, He D, Maasoumyhaghighi H, Nouri M, Wu M, et al. Therapeutic targeting of the p300\/CBP bromodomain enhances the efficacy of immune checkpoint blockade therapy. Oncogene. 2025,44:2386\u201395","journal-title":"Oncogene"},{"key":"7053_CR92","first-page":"1469","volume":"53","author":"J Lucas","year":"2018","unstructured":"Lucas J, Hsieh TC, Halicka HD, Darzynkiewicz Z, Wu JM. Upregulation of PD-L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3\/p300-mediated NF-\u03baB signaling. Int J Oncol. 2018;53:1469\u201380.","journal-title":"Int J Oncol"},{"key":"7053_CR93","doi-asserted-by":"publisher","first-page":"e2025840118","DOI":"10.1073\/pnas.2025840118","volume":"118","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Bastian IN, Long MD, Dow M, Li W, Liu T, et al. Activation of NF-\u03baB and p300\/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation. Proc Natl Acad Sci U S A. 2021;118:e2025840118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7053_CR94","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2019.12.008","volume":"80","author":"D Tewari","year":"2022","unstructured":"Tewari D, Patni P, Bishayee A, Sah AN, Bishayee A. Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: a novel therapeutic strategy. Semin Cancer Biol. 2022;80:1\u201317.","journal-title":"Semin Cancer Biol"},{"key":"7053_CR95","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2024.132686","volume":"271","author":"Y Yan","year":"2024","unstructured":"Yan Y, Dai T, Guo M, Zhao X, Chen C, Zhou Y, et al. A review of non-classical MAPK family member, MAPK4: a pivotal player in cancer development and therapeutic intervention. Int J Biol Macromol. 2024;271:132686.","journal-title":"Int J Biol Macromol"},{"key":"7053_CR96","doi-asserted-by":"publisher","first-page":"4507","DOI":"10.3390\/ijms21124507","volume":"21","author":"BY Shorning","year":"2020","unstructured":"Shorning BY, Dass MS, Smalley MJ, Pearson HB. The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR, MAPK, and WNT signaling. Int J Mol Sci. 2020;21:4507.","journal-title":"Int J Mol Sci"},{"key":"7053_CR97","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1530\/ERC-18-0383","volume":"26","author":"XH Luo","year":"2019","unstructured":"Luo XH, Liu JZ, Wang B, Men QL, Ju YQ, Yin FY, et al. KLF14 potentiates oxidative adaptation via modulating HO-1 signaling in castrate-resistant prostate cancer. Endocr Relat Cancer. 2019;26:181\u201395.","journal-title":"Endocr Relat Cancer"},{"key":"7053_CR98","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1038\/s41388-022-02327-5","volume":"41","author":"D Ji","year":"2022","unstructured":"Ji D, Shang G, Wei E, Jia Y, Wang C, Zhang Q, et al. Targeting CDCP1 gene transcription coactivated by BRD4 and CBP\/p300 in castration-resistant prostate cancer. Oncogene. 2022;41:3251\u201362.","journal-title":"Oncogene"},{"key":"7053_CR99","doi-asserted-by":"publisher","first-page":"4935","DOI":"10.7150\/thno.73223","volume":"12","author":"Q Chen","year":"2022","unstructured":"Chen Q, Yang B, Liu X, Zhang XD, Zhang L, Liu T. Histone acetyltransferases CBP\/p300 in tumorigenesis and CBP\/p300 inhibitors as promising novel anticancer agents. Theranostics. 2022;12:4935\u201348.","journal-title":"Theranostics"},{"key":"7053_CR100","doi-asserted-by":"publisher","first-page":"4716","DOI":"10.1021\/acs.jmedchem.9b02164","volume":"63","author":"F Wu","year":"2020","unstructured":"Wu F, Hua Y, Kaochar S, Nie S, Lin YL, Yao Y, et al. Discovery, structure-activity relationship, and biological activity of histone-competitive inhibitors of histone acetyltransferases P300\/CBP. J Med Chem. 2020;63:4716\u201331.","journal-title":"J Med Chem"},{"key":"7053_CR101","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1021\/acs.jmedchem.9b01721","volume":"63","author":"Y Yang","year":"2020","unstructured":"Yang Y, Zhang R, Li Z, Mei L, Wan S, Ding H, et al. Discovery of highly potent, selective, and orally efficacious p300\/CBP histone acetyltransferases inhibitors. J Med Chem. 2020;63:1337\u201360.","journal-title":"J Med Chem"},{"key":"7053_CR102","doi-asserted-by":"publisher","first-page":"5564","DOI":"10.1158\/0008-5472.CAN-17-0314","volume":"77","author":"L Jin","year":"2017","unstructured":"Jin L, Garcia J, Chan E, de la Cruz C, Segal E, Merchant M, et al. Therapeutic targeting of the CBP\/p300 bromodomain blocks the growth of castration-resistant prostate cancer. Cancer Res. 2017;77:5564\u201375.","journal-title":"Cancer Res"},{"key":"7053_CR103","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.ejmech.2018.01.087","volume":"147","author":"Q Xiang","year":"2018","unstructured":"Xiang Q, Wang C, Zhang Y, Xue X, Song M, Zhang C, et al. Discovery and optimization of 1-(1H-indol-1-yl)ethanone derivatives as CBP\/EP300 bromodomain inhibitors for the treatment of castration-resistant prostate cancer. Eur J Med Chem. 2018;147:238\u201352.","journal-title":"Eur J Med Chem"},{"key":"7053_CR104","doi-asserted-by":"publisher","first-page":"LB157","DOI":"10.1158\/1538-7445.AM2024-LB157","volume":"84","author":"J Li","year":"2024","unstructured":"Li J, Tu Z, Peng J, Fan L, Yu H, Wang F, Li X. Discovery of HP537, a potent and selective p300\/CBP inhibitor for the treatment of hematologic malignancies. Cancer Res. 2024;84:LB157.","journal-title":"Cancer Res"},{"key":"7053_CR105","doi-asserted-by":"crossref","unstructured":"Armstrong AJ, Gordon MS, Reimers MA, Sedkov A, Lipford K, Merhaut JS, Kumar S, Guichard SM, Shore N. Meeting Abstract. The courage study: a first-in-human phase 1 study of the CBP\/p300 inhibitor FT-7051 in men with metastatic castration-resistant prostate cancer. J Clin Oncol. 2021;39.","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS5085"},{"key":"7053_CR106","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/nature24028","volume":"550","author":"LM Lasko","year":"2017","unstructured":"Lasko LM, Jakob CG, Edalji RP, Qiu W, Montgomery D, Digiammarino EL, et al. Discovery of a selective catalytic p300\/CBP inhibitor that targets lineage-specific tumours. Nature. 2017;550:128\u201332.","journal-title":"Nature"},{"key":"7053_CR107","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.3390\/molecules26113162","volume":"26","author":"L Feng","year":"2021","unstructured":"Feng L, Yu S, Wang H, Yang S, Li X, Dai H, Zhao L, Jiang C, Wang Y. Synthesis and biological evaluation of spirocyclic chromane derivatives as a potential treatment of prostate cancer. Molecules. 2021;26:3162.","journal-title":"Molecules"},{"key":"7053_CR108","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910659","volume":"11","author":"Y Yan","year":"2019","unstructured":"Yan Y, Ma J, Wang D, Lin D, Pang X, Wang S, et al. The novel BET-CBP\/p300 dual inhibitor NEO2734 is active in SPOP mutant and wild-type prostate cancer. EMBO Mol Med. 2019;11:e10659.","journal-title":"EMBO Mol Med"},{"key":"7053_CR109","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000610","volume":"5","author":"N van Gils","year":"2021","unstructured":"van Gils N, Martia\u00f1ez Canales T, Vermue E, Rutten A, Denkers F, van der Deure T, et al. The novel oral BET-CBP\/p300 dual inhibitor NEO2734 is highly effective in eradicating acute myeloid leukemia blasts and stem\/progenitor cells. Hemasphere. 2021;5:e610.","journal-title":"Hemasphere"},{"key":"7053_CR110","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nchembio.1858","volume":"11","author":"DP Bondeson","year":"2015","unstructured":"Bondeson DP, Mares A, Smith IE, Ko E, Campos S, Miah AH, et al. Catalytic in vivo protein knockdown by small-molecule PROTACs. Nat Chem Biol. 2015;11:611\u20137.","journal-title":"Nat Chem Biol"},{"key":"7053_CR111","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1146\/annurev-pharmtox-030624-110238","volume":"65","author":"LY Wang","year":"2025","unstructured":"Wang LY, Hung CL, Wang TC, Hsu HC, Kung HJ, Lin KH. PROTACs as therapeutic modalities for drug discovery in castration-resistant prostate cancer. Annu Rev Pharmacol Toxicol. 2025;65:375\u201396.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"7053_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105245","volume":"106","author":"LY Wang","year":"2024","unstructured":"Wang LY. Selective p300 degradation via peptide PROTAC: a new therapeutic strategy for advanced prostate cancers. EBioMedicine. 2024;106:105245.","journal-title":"EBioMedicine"},{"key":"7053_CR113","doi-asserted-by":"publisher","first-page":"5275","DOI":"10.1021\/acs.jmedchem.3c02124","volume":"67","author":"Z Chen","year":"2024","unstructured":"Chen Z, Wang M, Wu D, Bai L, Xu T, Metwally H, et al. Discovery of CBPD-268 as an exceptionally potent and orally efficacious CBP\/p300 PROTAC degrader capable of achieving tumor regression. J Med Chem. 2024;67:5275\u2013304.","journal-title":"J Med Chem"},{"key":"7053_CR114","doi-asserted-by":"publisher","first-page":"5351","DOI":"10.1021\/acs.jmedchem.3c01789","volume":"67","author":"Z Chen","year":"2024","unstructured":"Chen Z, Wang M, Wu D, Zhao L, Metwally H, Jiang W, et al. Discovery of CBPD-409 as a highly potent, selective, and orally efficacious CBP\/p300 PROTAC degrader for the treatment of advanced prostate cancer. J Med Chem. 2024;67:5351\u201372.","journal-title":"J Med Chem"},{"key":"7053_CR115","doi-asserted-by":"publisher","first-page":"17290","DOI":"10.1021\/acs.jmedchem.4c01100","volume":"67","author":"M Ma","year":"2024","unstructured":"Ma M, Li M, Zhang C, Yang Z, Chen X, Lu P, et al. Discovery of a highly potent PROTAC degrader of p300\/CBP proteins for the treatment of enzalutamide-resistant prostate cancer. J Med Chem. 2024;67:17290\u2212318.","journal-title":"J Med Chem"},{"key":"7053_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105212","volume":"105","author":"D Zhang","year":"2024","unstructured":"Zhang D, Ma B, Liu D, Wu W, Zhou T, Gao Y, et al. Discovery of a peptide proteolysis-targeting chimera (PROTAC) drug of p300 for prostate cancer therapy. EBioMedicine. 2024;105:105212.","journal-title":"EBioMedicine"},{"key":"7053_CR117","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.eururo.2019.03.020","volume":"76","author":"WS Chen","year":"2019","unstructured":"Chen WS, Aggarwal R, Zhang L, Zhao SG, Thomas GV, Beer TM, et al. Genomic drivers of poor prognosis and Enzalutamide resistance in metastatic castration-resistant prostate cancer. Eur Urol. 2019;76:562\u201371.","journal-title":"Eur Urol"},{"key":"7053_CR118","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1530\/ERC-19-0488","volume":"27","author":"M Gruber","year":"2020","unstructured":"Gruber M, Ferrone L, Puhr M, Santer FR, Furlan T, Eder IE, et al. P300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer. Endocr Relat Cancer. 2020;27:187\u201398.","journal-title":"Endocr Relat Cancer"},{"key":"7053_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2022.e11171","volume":"8","author":"C Pilotto Heming","year":"2022","unstructured":"Pilotto Heming C, Muriithi W, Wanjiku Macharia L, Niemeyer Filho P, Moura-Neto V, Aran V. P-glycoprotein and cancer: what do we currently know? Heliyon. 2022;8:e11171.","journal-title":"Heliyon"},{"key":"7053_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115798","volume":"168","author":"M Strachowska","year":"2023","unstructured":"Strachowska M, Gronkowska K, Sobczak M, Grodzicka M, Michlewska S, Ko\u0142acz K, et al. I-CBP112 declines overexpression of ATP-binding cassette transporters and sensitized drug-resistant MDA-MB-231 and A549 cell lines to chemotherapy drugs. Biomed Pharmacother. 2023;168:115798.","journal-title":"Biomed Pharmacother"},{"key":"7053_CR121","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s41419-024-06422-1","volume":"15","author":"B Cevatemre","year":"2024","unstructured":"Cevatemre B, Bulut I, Dedeoglu B, Isiklar A, Syed H, Bayram OY, et al. Exploiting epigenetic targets to overcome taxane resistance in prostate cancer. Cell Death Dis. 2024;15:132.","journal-title":"Cell Death Dis"},{"key":"7053_CR122","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1158\/1078-0432.CCR-20-4391","volume":"27","author":"W Pan","year":"2021","unstructured":"Pan W, Zhang Z, Kimball H, Qu F, Berlind K, Stopsack KH, et al. Abiraterone acetate induces CREB1 phosphorylation and enhances the function of the CBP-p300 complex, leading to resistance in prostate cancer cells. Clin Cancer Res. 2021;27:2087\u201399.","journal-title":"Clin Cancer Res"},{"key":"7053_CR123","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.116130","volume":"171","author":"P Gou","year":"2024","unstructured":"Gou P, Zhang W. Protein lysine acetyltransferase CBP\/p300: a promising target for small molecules in cancer treatment. Biomed Pharmacother. 2024;171:116130.","journal-title":"Biomed Pharmacother"},{"key":"7053_CR124","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.3390\/biom10091266","volume":"10","author":"C Coste","year":"2020","unstructured":"Coste C, G\u00e9rard N, Dinh CP, Brugui\u00e8re A, Rouger C, Leong ST, Awang K, Richomme P, Charreau DS. Targeting MHC regulation using polycyclic polyprenylated acylphloroglucinols isolated from Garcinia bancana. Biomolecules. 2020;10:1266.","journal-title":"Biomolecules"},{"key":"7053_CR125","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.ccell.2025.03.012","volume":"43","author":"J Luo","year":"2025","unstructured":"Luo J, Solit DB. Leveraging real-world data to advance biomarker discovery and precision oncology. Cancer Cell. 2025;43:606\u201310.","journal-title":"Cancer Cell"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07053-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-07053-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-07053-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T14:04:06Z","timestamp":1759413846000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-07053-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":125,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7053"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-07053-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"assertion":[{"value":"4 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1045"}}